Analysis of the effect of clinical application of vaccine for esophageal cancer
10.3969/j.issn.1000-8179.20141175
- VernacularTitle:食管癌疫苗临床应用分析
- Author:
Donghong LIU
;
Lihua ZHU
;
Qingbo ZHANG
;
Xiuhua CAO
;
Enfu SHI
;
Hetian DING
- Publication Type:Journal Article
- Keywords:
tumor vaccine;
esophageal cancer;
tumor-soluble antigen;
superantigen SEC;
tumor biotherapy
- From:
Chinese Journal of Clinical Oncology
2014;(22):1459-1461
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the effects of the clinical applications of vaccine for esophageal cancer to provide treatment ba-sis. Methods:Tumor-soluble antigen was extracted from clinical samples of esophageal cancer tissue. Vaccine for esophageal cancer was prepared using antigen and superantigen staphylococcal enterotoxin C (SEC). One group of patients with esophageal cancer was treated with vaccine after surgery (treatment group). Another group of patients with esophageal cancer was treated using routine meth-ods (control group). After five years, the patients were followed up to analyze survival. Results:After five years of follow up, the sur-vival rates of treatment and control groups were 173/328 (49.71%) and 67/326 (20.55%), respectively. Survival rates significantly dif-fered between the two groups (P<0.05). Furthermore, the survival rates of the female patients were higher than those of the male pa-tients (P<0.05). In the treatment group, the survival rates of patients with low-differentiation cancer were higher than those of patients with high-differentiation cancer (P<0.05). In the control group, the survival rates of patients with low-differentiation cancer were lower than those of patients with high-differentiation cancer (P<0.05). Conclusion:Tumor vaccine prepared with esophageal cancer antigen and superantigen SEC could increase the survival rate of patients with esophageal cancer, particularly female patients and those with low-differentiation cancer.
